Novartis pays $3B for PI3Kα drug
Novartis agreed to acquire a pan‑mutant‑selective PI3Kα inhibitor from Synnovation Therapeutics for up to $3 billion—reinforcing demand for companion diagnostics and molecular profiling in breast cancer. That deal signals sustained industry investment in targeted therapies that will drive cytology specimens toward broader molecular testing. (novartis.com)
Novartis will acquire Pikavation Therapeutics, a wholly owned subsidiary of Synnovation that holds the SNV4818 program, under a deal structured as $2 billion cash upfront plus up to $1 billion in development, regulatory and commercial milestone payments; the companies said the transaction is expected to close in the first half of 2026. (businesswire.com) The lead asset being bought is SNV4818, an oral, pan‑mutant‑selective PI3Kα inhibitor currently being evaluated in a Phase 1/2 open‑label dose‑escalation and expansion study. (clinicaltrials.gov) The ongoing SNV4818 trial (NCT06736704) includes monotherapy cohorts, tumor‑agnostic enrollment for PI3Kα‑activating mutations, and combination arms with endocrine and CDK4/6 agents such as fulvestrant and palbociclib, with estimated enrollment of 320 and a primary completion date of April 2027. (clinicaltrials.gov) Synnovation reported dosing of the first patient in the SNV4818 Phase I study on February 24, 2025, with Timothy Yap, M.D., Ph.D., listed as a lead investigator at MD Anderson on early trial materials. (synnovationtx.com) SNV4818 is positioned to address PIK3CA‑mutant disease, a genomic subgroup found in roughly 40% of HR+/HER2‑ breast cancers according to multiple oncologic analyses, making mutation identification a key eligibility factor for the trial. (ascopubs.org) Real‑world testing patterns show tissue‑based PIK3CA analysis remains more common than plasma assays and that historically fewer than 40% of metastatic HR+/HER2‑ patients received comprehensive NGS, underscoring the diagnostic demand the SNV4818 program would create if clinical activity is confirmed. (journalofliquidbiopsy.com)
